<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.onclive.com/view/fda-removes-limitations-of-use-for-liso-cel-in-primary-central-nervous-system-lymphoma</loc>
      <lastmod>2026-11-17T21:22:18.713Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:22:18.713Z</news:publication_date>
        <news:title><![CDATA[FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/quality-improvement-and-egfr-mutatnt-lung-cancer-survivorship-research-help-shape-fellowship-training</loc>
      <lastmod>2026-11-17T21:16:57.173Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:16:57.173Z</news:publication_date>
        <news:title><![CDATA[Quality Improvement and EGFR-mutatnt Lung Cancer Survivorship Research Help Shape Fellowship Training]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/long-term-sano-data-reinforce-active-surveillance-as-an-option-in-esophageal-cancer</loc>
      <lastmod>2026-11-17T21:08:23.383Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:08:23.383Z</news:publication_date>
        <news:title><![CDATA[Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/perioperative-targeted-therapy-fills-the-immunotherapy-gap-in-oncogene-driven-early-stage-nsclc</loc>
      <lastmod>2026-11-17T20:47:25.166Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:47:25.166Z</news:publication_date>
        <news:title><![CDATA[Perioperative Targeted Therapy Fills the Immunotherapy Gap in Oncogene-Driven Early-Stage NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-accepts-snda-for-selinexor-plus-ruxolitinib-in-myelofibrosis</loc>
      <lastmod>2026-11-17T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T18:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-approves-neladalkib-for-locally-advanced-or-metastatic-alk-nsclc</loc>
      <lastmod>2026-11-17T17:40:32.625Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:40:32.625Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/tcr-based-strategies-and-tolerable-combinations-begin-to-narrow-the-outcome-gap-in-uveal-melanoma</loc>
      <lastmod>2026-11-17T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:00:00Z</news:publication_date>
        <news:title><![CDATA[TCR-Based Strategies and Tolerable Combinations Begin to Narrow the Outcome Gap in Uveal Melanoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/her2-mutation-and-overexpression-in-lung-cancer</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[HER2 Mutation and Overexpression in Lung Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/rosella-trial-design-survival-results-and-subgroup-findings</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[ROSELLA Trial Design, Survival Results, and Subgroup Findings]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/pd-l1-and-immunotherapy-selection-in-gastrointestinal-cancers</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[PD-L1 and Immunotherapy Selection in Gastrointestinal Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/using-relacorilant-plus-nab-paclitaxel-earlier-in-platinum-resistance</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Using Relacorilant Plus Nab-Paclitaxel Earlier in Platinum Resistance]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/pertuzumab-biosimilar-gains-fda-approval-for-her2-breast-cancer</loc>
      <lastmod>2026-11-16T23:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T23:05:00Z</news:publication_date>
        <news:title><![CDATA[Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/localized-prostate-cancer-2026-update-psma-pet-arpi-strategies-and-new-trials-reshape-localized-management</loc>
      <lastmod>2026-11-16T22:15:27.207Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:15:27.207Z</news:publication_date>
        <news:title><![CDATA[Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-cortes-on-the-rationale-behind-the-optic-trial-in-cml</loc>
      <lastmod>2026-11-16T22:14:10.151Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:14:10.151Z</news:publication_date>
        <news:title><![CDATA[Dr Cortes on the Rationale Behind the OPTIC Trial in CML]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/daraxonrasib-gains-ec-approval-in-previously-treated-metastatic-pancreatic-cancer</loc>
      <lastmod>2026-11-16T22:00:22.976Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:00:22.976Z</news:publication_date>
        <news:title><![CDATA[Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/cretostimogene-improves-rfs-in-intermediate-risk-and-high-grade-ta-nmibc</loc>
      <lastmod>2026-11-16T20:57:17.577Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:57:17.577Z</news:publication_date>
        <news:title><![CDATA[Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-approves-giredestrant-plus-everolimus-for-er-her2-esr1-mutated-metastatic-breast-cancer</loc>
      <lastmod>2026-11-16T20:42:10.163Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:42:10.163Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/onvansertib-earns-fda-fast-track-designation-in-first-line-ras-mutated-mcrc</loc>
      <lastmod>2026-11-16T15:47:09.610Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:47:09.610Z</news:publication_date>
        <news:title><![CDATA[Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-issues-crl-to-ivonescimab-plus-chemo-for-locally-advanced-or-metastatic-nsclc</loc>
      <lastmod>2026-11-16T13:39:26.231Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:39:26.231Z</news:publication_date>
        <news:title><![CDATA[FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/individualizing-cll-sequencing-and-closing-knowledge-gaps</loc>
      <lastmod>2026-11-16T13:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:30:00Z</news:publication_date>
        <news:title><![CDATA[Individualizing CLL Sequencing and Closing Knowledge Gaps]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/car-t-bridging-and-pirtobrutinib-triplet-therapy-in-cll</loc>
      <lastmod>2026-11-16T13:25:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:25:00Z</news:publication_date>
        <news:title><![CDATA[CAR T Bridging and Pirtobrutinib Triplet Therapy in CLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/venetoclax-retreatment-and-post-btk-inhibitor-choices-in-cll</loc>
      <lastmod>2026-11-16T13:20:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:20:00Z</news:publication_date>
        <news:title><![CDATA[Venetoclax Retreatment and Post-BTK Inhibitor Choices in CLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/managing-btk-inhibitor-toxicity-and-cardiovascular-risk-in-cll</loc>
      <lastmod>2026-11-16T13:15:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:15:00Z</news:publication_date>
        <news:title><![CDATA[Managing BTK Inhibitor Toxicity and Cardiovascular Risk in CLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/cll-frontline-triplets-and-btk-inhibitor-choice-at-relapse</loc>
      <lastmod>2026-11-16T13:10:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:10:00Z</news:publication_date>
        <news:title><![CDATA[CLL Frontline Triplets and BTK Inhibitor Choice at Relapse]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/second-line-sunvozertinib-and-dose-selection</loc>
      <lastmod>2026-11-16T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Second-Line Sunvozertinib and Dose Selection]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dellphi-305-moves-tarlatamab-into-first-line-maintenance-for-es-sclc</loc>
      <lastmod>2026-11-16T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:05:00Z</news:publication_date>
        <news:title><![CDATA[DeLLphi-305 Moves Tarlatamab Into First-Line Maintenance for ES-SCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fixed-duration-therapy-and-frontline-pirtobrutinib-in-cll</loc>
      <lastmod>2026-11-16T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Fixed-Duration Therapy and Frontline Pirtobrutinib in CLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/coordinating-care-and-comparing-til-and-tcr-cell-therapies</loc>
      <lastmod>2026-11-16T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Coordinating Care and Comparing TIL and TCR Cell Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/balancing-benefit-and-toxicity-with-lurbinectedin-maintenance-in-the-imforte-era</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Balancing Benefit and Toxicity With Lurbinectedin Maintenance in the IMforte Era]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/brain-metastases-eligibility-and-chemotherapy-free-preferences</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Brain Metastases Eligibility and Chemotherapy-Free Preferences]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/when-and-how-to-refer-patients-for-cellular-therapy</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[When and How to Refer Patients for Cellular Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/differentiating-btk-inhibitors-in-cll-treatment-selection</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Differentiating BTK Inhibitors in CLL Treatment Selection]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/db107-rrv-plus-db107-fc-can-be-delivered-with-radiation-in-newly-diagnosed-high-grade-glioma</loc>
      <lastmod>2026-11-15T23:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-15T23:05:00Z</news:publication_date>
        <news:title><![CDATA[DB107-RRV Plus DB107-FC Can Be Delivered With Radiation in Newly Diagnosed High-Grade Glioma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-schaff-on-safety-and-os-outcomes-with-l19tnf-plus-lomustine-in-recurrent-glioblastoma</loc>
      <lastmod>2026-11-15T22:25:07.427Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-15T22:25:07.427Z</news:publication_date>
        <news:title><![CDATA[Dr Schaff on Safety and OS Outcomes With L19TNF Plus Lomustine in Recurrent Glioblastoma]]></news:title>
      </news:news>
	</url></urlset>